2021 annual financial data
Kyverna Therapeutics 2021 Operating margin
Direct answer
Operating margin was -465.81%.
Operating income was -26,346,000 USD and net income was -26,350,000 USD.
Operating cash flow was -22,155,000 USD.
Get free Kyverna Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 5,656,000 USD
- Operating income
- -26,346,000 USD
- Net income
- -26,350,000 USD
- Operating cash flow
- -22,155,000 USD